Article ; Online: Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem.
2022 Volume 41, Issue 5, Page(s) 853–858
Abstract: Background: The treatment of infections caused by OXA-48/CTX-M-coproducing Enterobacterales may be based on new beta-lactam/beta-lactamase inhibitors, such as ceftazidime/avibactam (CZA), or on high dose of meropenem (MER). However, bacterial density at ...
Abstract | Background: The treatment of infections caused by OXA-48/CTX-M-coproducing Enterobacterales may be based on new beta-lactam/beta-lactamase inhibitors, such as ceftazidime/avibactam (CZA), or on high dose of meropenem (MER). However, bacterial density at the infection site may vary widely, and the inoculum effect of such antimicrobial strategies has never been specifically investigated. To determine if CZA or MER susceptibilities are impacted by high inocula of Enterobacterales co-expressing both enzymes: OXA-48 like and CTX-M. Methods: Determination of an inoculum effect was performed with a standard inoculum of 10 Results: Thirty-nine isolates of ceftazidime-resistant Enterobacterales were included of which 27 (70%) co-expressed OXA-48 + CTX-M-15, 6 (15%) OXA-48 + CTX-M-14, and 6 (15%) OXA-181 + CTX-M-15. The susceptibility to the CZA combination was preserved whatever the inoculum used. Regarding MER, 24 (61.5%) of the isolates were susceptible to MER with the standard inoculum, 19 (48.7%) with a twofold increase, and only 15 (38.5%) with a tenfold increase. Conclusion: We showed that in vitro inoculum effect was observed with meropenem but not with CZA for OXA-48- combined with CTX-M-producing Enterobacterales. |
---|---|
MeSH term(s) | Anti-Bacterial Agents/pharmacology ; Azabicyclo Compounds/pharmacology ; Ceftazidime/pharmacology ; Drug Combinations ; Enterobacteriaceae/drug effects ; Meropenem/pharmacology ; Microbial Sensitivity Tests ; beta-Lactamase Inhibitors/pharmacology ; beta-Lactamases/genetics |
Chemical Substances | Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; avibactam, ceftazidime drug combination ; beta-Lactamase Inhibitors ; avibactam (7352665165) ; Ceftazidime (9M416Z9QNR) ; beta-Lactamases (EC 3.5.2.6) ; Meropenem (FV9J3JU8B1) |
Language | English |
Publishing date | 2022-03-23 |
Publishing country | Germany |
Document type | Journal Article |
ZDB-ID | 603155-9 |
ISSN | 1435-4373 ; 0934-9723 ; 0722-2211 |
ISSN (online) | 1435-4373 |
ISSN | 0934-9723 ; 0722-2211 |
DOI | 10.1007/s10096-022-04430-7 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1732: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.